newsfilter
← Latest News
Business Wire·

Immunome Reports First Quarter 2026 Financial Results and Provides Business Update

New Drug Application (NDA) submitted to the U.S. Food and Drug Administration (FDA) in April 2026 seeking approval of varegacestat for the treatment of adults with desmoid tumors Detailed Phase 3 RINGSIDE data